Hetero COVID drug Molnupiravir shows positive results in Phase III trials
Hyderabad: Hetero, a globally renowned vertically integrated pharmaceutical organization has recently announced the positive results of Phase III trials of Hetero's Movfor (Molnupiravir), an investigational oral antiviral COVID-19 medicine.
The results, presented as an Oral Abstract at the Conference on Retroviruses and Opportunistic Infections (CROI) held virtually February 12–16, 2022, demonstrated that Molnupiravir along with Standard of Care (SOC) reduced the risk of hospitalization by over 65% compared to SOC alone. Early viral clearance (negative RT-PCR) and significant clinical improvement were observed within 5 days of administering the antiviral drug. There were no fatalities reported during the study. Under the Phase III trials, one of the studies included 1218 COVID-19 patients (with SPO2>93% and COVID-19 symptoms as per ICMR COVID-19 guidelines). The study enrolled eligible patients, within 5 days of symptom onset, and were administered with Molnupiravir capsules (800 mg twice daily) + Standard of Care (SOC) or SOC alone for 5 days.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.